The Celgene Story Is Bigger Than Revlimid Now; Argus Upgrades

By: via Benzinga
Argus upgraded Celgene Corporation (NASDAQ: CELG) Monday on the strength of a diversified drug portfolio and a “robust development ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.